TN2009000285A1 - Human cytomegalovirus neutralising antibodies and use thereof - Google Patents

Human cytomegalovirus neutralising antibodies and use thereof

Info

Publication number
TN2009000285A1
TN2009000285A1 TNP2009000285A TN2009000285A TN2009000285A1 TN 2009000285 A1 TN2009000285 A1 TN 2009000285A1 TN P2009000285 A TNP2009000285 A TN P2009000285A TN 2009000285 A TN2009000285 A TN 2009000285A TN 2009000285 A1 TN2009000285 A1 TN 2009000285A1
Authority
TN
Tunisia
Prior art keywords
antibodies
human cytomegalovirus
neutralising antibodies
well
epitopes
Prior art date
Application number
TNP2009000285A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Annalilsa Macagno
Original Assignee
Inst Res In Biomedecine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Res In Biomedecine filed Critical Inst Res In Biomedecine
Publication of TN2009000285A1 publication Critical patent/TN2009000285A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TNP2009000285A 2007-01-04 2009-07-03 Human cytomegalovirus neutralising antibodies and use thereof TN2009000285A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof
PCT/IB2008/001111 WO2008084410A2 (fr) 2007-01-04 2008-01-03 Anticorps neutralisants des cytomégalovirus humains et leur utilisation

Publications (1)

Publication Number Publication Date
TN2009000285A1 true TN2009000285A1 (en) 2010-12-31

Family

ID=37801734

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000285A TN2009000285A1 (en) 2007-01-04 2009-07-03 Human cytomegalovirus neutralising antibodies and use thereof

Country Status (32)

Country Link
US (4) US7955599B2 (fr)
EP (3) EP2118140B1 (fr)
JP (2) JP5710123B2 (fr)
KR (2) KR101541927B1 (fr)
CN (1) CN101657467B (fr)
AU (1) AU2008204258B2 (fr)
BR (1) BRPI0806185A2 (fr)
CA (1) CA2673755C (fr)
CO (1) CO6220862A2 (fr)
CR (1) CR10961A (fr)
CY (1) CY1114271T1 (fr)
DK (1) DK2118140T3 (fr)
EC (1) ECSP099547A (fr)
ES (2) ES2426987T3 (fr)
GB (1) GB0700133D0 (fr)
GT (1) GT200900188A (fr)
HK (2) HK1139158A1 (fr)
HR (1) HRP20130877T1 (fr)
IL (1) IL199585A (fr)
MA (1) MA31225B1 (fr)
MX (1) MX2009007320A (fr)
MY (2) MY150709A (fr)
NZ (1) NZ578844A (fr)
PL (1) PL2118140T3 (fr)
PT (2) PT2118140E (fr)
RU (1) RU2469045C2 (fr)
SG (3) SG191635A1 (fr)
SI (1) SI2118140T1 (fr)
TN (1) TN2009000285A1 (fr)
UA (1) UA100682C2 (fr)
WO (1) WO2008084410A2 (fr)
ZA (1) ZA200905408B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2009021150A2 (fr) 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP3178845A1 (fr) 2008-07-16 2017-06-14 Institute for Research in Biomedicine Anticorps neutralisant le cytomégalovirus humain et utilisation de ceux-ci
CA2731686C (fr) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Anticorps neutralisant anti-virus influenza a et leurs utilisations
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2420572B1 (fr) 2009-04-01 2015-03-25 Evec Incorporated ANTICORPS MONOCLONAL POUVANT SE LIER À UN ÉPITOPE DISCONTINU SPÉCIFIQUE APPARAISSANT DANS UNE RÉGION AD1 D'UNE GLYCOPROTÉINE gB DE CYTOMÉGALOVIRUS HUMAIN, ET FRAGMENT DE LIAISON À UN ANTIGÈNE DUDIT ANTICORPS
SG181901A1 (en) 2009-12-23 2012-08-30 4Antibody Ag Binding members for human cytomegalovirus
RU2613421C2 (ru) 2010-06-16 2017-03-16 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
US9139659B2 (en) 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
WO2014099908A1 (fr) * 2012-12-17 2014-06-26 Genentech, Inc. Méthodes d'inhibition de l'infection virale chez les patient greffés
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
WO2016011035A2 (fr) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralisation d'anticorps anti-grippe b et leurs utilisations
US20160069643A1 (en) * 2014-09-06 2016-03-10 Philip Lyren Weapon Targeting System
MX2017015189A (es) 2015-06-01 2018-04-13 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
KR20180101483A (ko) 2016-01-08 2018-09-12 에임 쎄라퓨틱스 비.브이. 치료적 항-ｃｄ９ 항체
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
EP3749690A1 (fr) * 2018-02-05 2020-12-16 Stichting VU Anticorps anti-us28 agonistes inverses
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061943A (en) 1964-09-10 1967-03-15 Carter S Ink Co Marking composition
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3581400D1 (de) 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
KR910000736B1 (ko) 1985-12-06 1991-02-06 데이진 가부시키가이샤 사이토메갈로 바이러스에 대한 사람·모노클로날 항체와 그 제조방법
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (fr) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Anticorps monoclonaux specifiques contre une glycoproteine de cytomegalovirus
WO1991005876A1 (fr) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Cocktail d'anticorps monoclonaux specifiques du cytomegalovirus humain
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) * 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
ATE173543T1 (de) 1992-04-10 1998-12-15 Thomas Totterman Verfahren zum nachweis einer cmv-infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994016724A1 (fr) 1993-01-21 1994-08-04 Zaia John A Prevention et traitement de cytomegalovirus par l'aminopeptidase
WO1994016730A1 (fr) 1993-01-28 1994-08-04 Sandoz Pharmaceutical Corporation Anticorps monoclonaux humains contre le cytomegalovirus
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1994025490A1 (fr) 1993-04-30 1994-11-10 The Scripps Research Institute Anticorps monoclonaux humains diriges contre des cytomegalovirus humains et procedes s'y rapportant
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (fr) 1994-07-26 1997-01-15 Biotest Ag Polypeptides et protéines fusionnées contenant la structure à lecture ouverte UL57 ou la séquence C-terminal de la protéine pp150 de tégument de HCMV, oligonucléotides et trousses diagnostiques correspondantes
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
WO1998002746A1 (fr) 1996-07-12 1998-01-22 Akzo Nobel N.V. Reactif de peptides permettant la detection de cytomegalovirus (cmv) humain
WO1998006408A1 (fr) 1996-08-14 1998-02-19 The Wistar Institute Of Anatomy And Biology Procedes et compositions pour empecher ou pour retarder le developpement de lesions atherosclereuses
EP1003841A4 (fr) 1997-01-30 2002-04-17 Cedars Sinai Medical Center Creation d'une lignee cellulaire lymphomateuse a hsv-8+, virus produit, anticorps, methode diagnostique et trousse pour detecter l'infection par le hsv-8
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
AU756222B2 (en) 1997-07-18 2003-01-09 Connaught Laboratories Limited Nucleic acid vaccines encoding G protein of respiratory syncytial virus
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
JP3764047B2 (ja) 1998-03-12 2006-04-05 ジェネンテック・インコーポレーテッド 網膜ニューロン死の防止及び眼病の治療方法
AU5503899A (en) 1998-06-29 2000-01-17 Wolfgang Bergter Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
WO2003085121A2 (fr) 2002-04-01 2003-10-16 Agensys, Inc. Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
WO2004076677A2 (fr) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
WO2004076645A2 (fr) 2003-02-27 2004-09-10 University Of Massachusetts Compositions et methodes de traitement du cytomegalovirus
WO2004078926A2 (fr) 2003-02-28 2004-09-16 Board Of Trustees Operating Michigan State University Marqueurs immunologiques
KR101541658B1 (ko) 2004-06-21 2015-08-07 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
ATE503770T1 (de) 2005-03-14 2011-04-15 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
JP5431730B2 (ja) 2005-12-16 2014-03-05 リボバックス バイオテクノロジーズ ソシエテ アノニム 不死化された抗体分泌細胞を得る方法
WO2007094423A1 (fr) 2006-02-15 2007-08-23 Evec Incorporated Anticorps monoclonal humain capable de se lier au cytomegalovirus humain et domaine de liaison antigene de l'anticorps
EP2024507B1 (fr) 2006-05-19 2015-07-22 Technion Research and Development Foundation Ltd. Protéines de fusion, leurs utilisations et leurs procédés de production
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US8153129B2 (en) 2006-12-15 2012-04-10 Ribovax Biotechnologies S.A. Antibodies against human cytimegalovirus (HCMV)
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
WO2009024445A1 (fr) 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Anticorps dirigés contre le cytomégalovirus humain (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
AU2008359583B2 (en) 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
EP3178845A1 (fr) 2008-07-16 2017-06-14 Institute for Research in Biomedicine Anticorps neutralisant le cytomégalovirus humain et utilisation de ceux-ci

Also Published As

Publication number Publication date
ZA200905408B (en) 2010-05-26
HK1174344A1 (en) 2013-06-07
KR20140101884A (ko) 2014-08-20
ECSP099547A (es) 2009-11-30
GT200900188A (es) 2011-11-29
CO6220862A2 (es) 2010-11-19
RU2469045C2 (ru) 2012-12-10
KR101541927B1 (ko) 2015-08-05
GB0700133D0 (en) 2007-02-14
EP2118140B1 (fr) 2013-06-19
DK2118140T3 (da) 2013-07-01
AU2008204258A1 (en) 2008-07-17
EP2860189A2 (fr) 2015-04-15
NZ578844A (en) 2012-08-31
KR101659306B1 (ko) 2016-09-23
IL199585A (en) 2014-07-31
JP5710123B2 (ja) 2015-04-30
US20130101604A1 (en) 2013-04-25
US20140056914A1 (en) 2014-02-27
CN101657467B (zh) 2013-11-06
US9149524B2 (en) 2015-10-06
JP2014141501A (ja) 2014-08-07
HK1139158A1 (en) 2010-09-10
CN101657467A (zh) 2010-02-24
US20120076802A1 (en) 2012-03-29
EP2860189A3 (fr) 2015-07-29
EP2118140A2 (fr) 2009-11-18
CY1114271T1 (el) 2016-08-31
WO2008084410A3 (fr) 2008-12-24
MY150709A (en) 2014-02-28
KR20090127256A (ko) 2009-12-10
SI2118140T1 (sl) 2013-10-30
US20080213265A1 (en) 2008-09-04
EP2487187A3 (fr) 2012-11-21
PL2118140T3 (pl) 2013-11-29
AU2008204258B2 (en) 2012-09-06
ES2526907T3 (es) 2015-01-16
PT2487187E (pt) 2015-02-05
JP2010516229A (ja) 2010-05-20
HRP20130877T1 (hr) 2013-10-25
SG177943A1 (en) 2012-02-28
UA100682C2 (ru) 2013-01-25
CA2673755A1 (fr) 2008-07-17
EP2487187A2 (fr) 2012-08-15
ES2426987T3 (es) 2013-10-28
PT2118140E (pt) 2013-08-29
WO2008084410A2 (fr) 2008-07-17
US7955599B2 (en) 2011-06-07
US8309089B2 (en) 2012-11-13
US8545848B2 (en) 2013-10-01
SG191635A1 (en) 2013-07-31
MA31225B1 (fr) 2010-03-01
EP2487187B1 (fr) 2014-10-22
MY161200A (en) 2017-04-14
BRPI0806185A2 (pt) 2011-08-30
MX2009007320A (es) 2010-02-22
RU2009129403A (ru) 2011-02-10
CR10961A (es) 2009-11-20
CA2673755C (fr) 2016-04-05
SG192399A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
TN2009000285A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
PH12017501732A1 (en) Therapeutic antibodies and their uses
MY156286A (en) Human il-23 antigen binding proteins
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MY160590A (en) Cd127 binding proteins
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EP3539988A3 (fr) Anticorps monoclonaux contre her2
WO2011130434A3 (fr) Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
JO3246B1 (ar) اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
IN2014MN02231A (fr)
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
TN2010000621A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
TN2010000374A1 (en) Antibodies directed to angiopoietin -1 and angiopoietin-2 and use thereof
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.